What is CSPC prostate?
Prostate cancer that responds to treatment to lower testosterone is called castration-sensitive prostate cancer (CSPC).
What is mCRPC prostate cancer?
It’s a somewhat long and confusing name, but the term metastatic castration-resistant prostate cancer (mCRPC) refers to a cancer that has spread (metastasized) beyond your prostate gland and for which hormone therapy is no longer effective in stopping or slowing the disease.
How long can you live mCRPC?
From the 53 patients with mCRPC, 27 survived beyond 24 months; thus the two-year life expectancy for these patients was 50.9% (Table I). Almost all patients with mCRPC were above 65 years of age, only three patients presented with this disease in ages below 55 years.
What stage is mCRPC?
In the advanced form of prostate cancer, it becomes metastatic. It spreads beyond the prostate to other parts of the body. With Metastatic Castration-Resistant Prostate Cancer (mCRPC), hormone therapy no longer stops cancer growth.
What are side effects of abiraterone?
Side Effects
- Bladder pain.
- bloating or swelling of the face, arms, hands, lower legs, or feet.
- bloody or cloudy urine.
- bone pain or fracture.
- chest pain or discomfort.
- decreased urine.
- difficult, burning, or painful urination.
- fast, pounding, or irregular heartbeat or pulse.
How long do you take abiraterone?
by Drugs.com The length of time patients remain on Zytiga varies. The median amount of time patients with metastatic prostate cancer remained on Zytiga ranged from 8 to 24 months, according to the results from clinical trials used to gain Food and Drug Administration (FDA) approval for Zytiga in the US.
Can mCRPC be cured?
No cure yet exists for mCRPC, but prolongation of survival is possible with new treatments, some of which have been approved by the U.S. Food and Drug Administration (FDA) or are being evaluated in clinical trials.
What is castration-resistant prostate cancer (CRPC)?
Castration-resistant prostate cancer (CRPC) is a type of prostate cancer. If you have CRPC, you may take hormonal medications, chemotherapy, or immunotherapy.
What is advanced prostate cancer?
Advanced prostate cancer has been known under a number of names over the years, including hormone-resistant prostate cancer (HRPC) and androgen-insensitive prostate cancer (AIPC).
Why do some subtypes of CrPC become resistant to anti-androgen therapies?
Several mechanisms have been proposed to explain this acquired resistance, many of which are driven by androgen receptor (AR). Recent findings, however, sub-classified CRPC by downregulation/absence of AR in certain subtypes that consequently do not respond to anti-androgen therapies.
What does CrPC stand for?
Definition. Most recently, the terms CRPC or castration recurrent prostate cancer were introduced with the realization that intracrine/paracrine androgen production plays is significant in the resistant of prostate cancer cells to testosterone suppression therapy. 1 In their second publication, the Prostate Cancer Working Group (PCWG2)…
https://www.youtube.com/watch?v=uIdNA2nr91M